Menarini Group ’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer
Submission supported by results from the pivotal...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | HER2 | Men | New Drug Applications | Oral Cancer